Viiv

Quote
anonymous said:
Ha- yes. Just like Juluca, Dovato, and CAB for treatment we’re going to “save us.”
Click to expand...
Not with the FRM team in place and access issues everywhere. A 25 step process to get an injectable that has GSK restricted access. Viiv stands in their own way and focuses on the weirdest most childish marketing babysitting practices. Never felt so demoralized as when at Viiv. Terrible management from above that is completely invisible and uninvolved- never on calls.
 






anonymous said:
Not with the FRM team in place and access issues everywhere. A 25 step process to get an injectable that has GSK restricted access. Viiv stands in their own way and focuses on the weirdest most childish marketing babysitting practices. Never felt so demoralized as when at Viiv. Terrible management from above that is completely invisible and uninvolved- never on calls.
Click to expand...
I agree with all this, and our products suck too!
 






anonymous said:
Not with the FRM team in place and access issues everywhere. A 25 step process to get an injectable that has GSK restricted access. Viiv stands in their own way and focuses on the weirdest most childish marketing babysitting practices. Never felt so demoralized as when at Viiv. Terrible management from above that is completely invisible and uninvolved- never on calls.
Click to expand...
Viiv is a revolving door. People continue to realize there is no future for them and management could care less. The good ones are leaving and others hang on hoping for a layoff and others just want to collect s paycheck. This place is terrible. Once a great place with such hope and how they treat their salesforce is a disgrace. If you want to feel like a preschooler and then a management team that spends hours a week on worthless conference calls sharing their opinions with directors that don’t know your name or anything firsthand about you. Then throw in the people that talk shit about you to customers and to teammates. Viiv will destroy your reputation, your career and your sanity. Run the F away from this overcrowded place. They don’t know what they are doing. Instead of valuing people and becoming a special company, they focused on Gilead and how to be more like them. Viiv lost sight with the goal, the patients, the doctors, the people that work on the same teams. It’s gross all the Gilead bashing instead of making something different and respectful and actually easy to access. GSK ruined the injectable business and prep will be limited and expensive and not covered. Insurance company’s don’t support viiv or the manager care. Enough of the FRM team sucks and the others don’t have the resources they need to do their jobs efficiently. Some FRMs don’t know how to do their job or how to act in front of doctors. Pure 100% shit show of launching these products the past 6 years and the future PREP teams. Bye Viiv bye business everywhere the thought leaders think that you are a joke. Other companies are launching right behind Viiv and other companies that will make access and ease of use a priority.
 
























Viiv could have saved many good people from leaving if they just treated their people right. Allow growth and opportunities and allow them to interview for positions internally. A bunch of miserable people working there.
 






























anonymous said:
LOL. Do you know how much better the Gilead pay and reputation is? I’d be shocked if anyone left there to come to this place. Career suicide
Click to expand...
Our company sucks. Our products suck. We have zero respect in the community. The only reason anyone would leave Gilead and come here would be for a big promotion, or a promise that this company would soon break. No way any sane person makes the jump unless forced.
 
























anonymous said:
The heat is coming down which I completely get. Since July 2017 when we went to 3 per pod (the furthest thing from specialty sales ever) we have seen the following:

1. Recycled RSDs from respiratory who popped into ViiV, bury us in metrics, and then head to RTP. Plenty of examples where their districts were bottom 10% and they ran off talent and micromanaged the rest—and got promoted after 2 yrs.

2. Senior leaders who built the positive culture retired (Bill Collier, Marlon Pittman, etc.). Instead we got Pickett and the GSK crew.

3. Bailed on Triumeq while we had decent share for 2DR (Juluca, Dovato, Cabenuva, and the entire future pipeline combined don’t equal the amount that Triumeq/Tivicay LOST and are still losing. I doubt the entire 2DR sales—all drug sales combined will EVER reach over $200m total (net) while the several billion dollar Triumeq and Tivicay, 1-2 punch keeps bleeding a fortune. Of course TAF hurt Tivicay (remember when Tivicay+Descovy was what IDs said was the gold standard). Well—GILEAD listened and Biktarvy faced no competition (we were doomed).

4. Metrics hell with number of programs, calls, bathroom breaks literally micromanaged. And the never break your 3-4 week routing ever.

5. Going from 3 up to 4 up. What next, can we go 5 up? That should fix things, lol.

At the end of the day, we lost all respect with IDs and in the HIV advocacy community for pushing the 2DR regimen (with 48wk data initially, then 96wk, etc.) when the standard of care was and is 3DR.

Why are we surprised? I am not. In hindsight I wish my RSD had pushed me out or let me take early retirement.
Click to expand...
 






anonymous said:
The heat is coming down which I completely get. Since July 2017 when we went to 3 per pod (the furthest thing from specialty sales ever) we have seen the following:

1. Recycled RSDs from respiratory who popped into ViiV, bury us in metrics, and then head to RTP. Plenty of examples where their districts were bottom 10% and they ran off talent and micromanaged the rest—and got promoted after 2 yrs.

2. Senior leaders who built the positive culture retired (Bill Collier, Marlon Pittman, etc.). Instead we got Pickett and the GSK crew.

3. Bailed on Triumeq while we had decent share for 2DR (Juluca, Dovato, Cabenuva, and the entire future pipeline combined don’t equal the amount that Triumeq/Tivicay LOST and are still losing. I doubt the entire 2DR sales—all drug sales combined will EVER reach over $200m total (net) while the several billion dollar Triumeq and Tivicay, 1-2 punch keeps bleeding a fortune. Of course TAF hurt Tivicay (remember when Tivicay+Descovy was what IDs said was the gold standard). Well—GILEAD listened and Biktarvy faced no competition (we were doomed).

4. Metrics hell with number of programs, calls, bathroom breaks literally micromanaged. And the never break your 3-4 week routing ever.

5. Going from 3 up to 4 up. What next, can we go 5 up? That should fix things, lol.

At the end of the day, we lost all respect with IDs and in the HIV advocacy community for pushing the 2DR regimen (with 48wk data initially, then 96wk, etc.) when the standard of care was and is 3DR.

Why are we surprised? I am not. In hindsight I wish my RSD had pushed me out or let me take early retirement.
Click to expand...
 






COLLIER AND PITTMAN??? Those f-tards did nothing positive. At the end of Pittman’s tenure his personal life was spinning out of control and going down Bruce Jenner’s pathway. Collier just was a pill, a total pill.


anonymous said:
The heat is coming down which I completely get. Since July 2017 when we went to 3 per pod (the furthest thing from specialty sales ever) we have seen the following:

1. Recycled RSDs from respiratory who popped into ViiV, bury us in metrics, and then head to RTP. Plenty of examples where their districts were bottom 10% and they ran off talent and micromanaged the rest—and got promoted after 2 yrs.

2. Senior leaders who built the positive culture retired (Bill Collier, Marlon Pittman, etc.). Instead we got Pickett and the GSK crew.

3. Bailed on Triumeq while we had decent share for 2DR (Juluca, Dovato, Cabenuva, and the entire future pipeline combined don’t equal the amount that Triumeq/Tivicay LOST and are still losing. I doubt the entire 2DR sales—all drug sales combined will EVER reach over $200m total (net) while the several billion dollar Triumeq and Tivicay, 1-2 punch keeps bleeding a fortune. Of course TAF hurt Tivicay (remember when Tivicay+Descovy was what IDs said was the gold standard). Well—GILEAD listened and Biktarvy faced no competition (we were doomed).

4. Metrics hell with number of programs, calls, bathroom breaks literally micromanaged. And the never break your 3-4 week routing ever.

5. Going from 3 up to 4 up. What next, can we go 5 up? That should fix things, lol.

At the end of the day, we lost all respect with IDs and in the HIV advocacy community for pushing the 2DR regimen (with 48wk data initially, then 96wk, etc.) when the standard of care was and is 3DR.

Why are we surprised? I am not. In hindsight I wish my RSD had pushed me out or let me take early retirement.
Click to expand...
 


















Top Bottom
Back
Quote